



FOR IMMEDIATE RELEASE

Oxford Gene Technology

NimbleGen Systems, Inc.

Contact:

Nicola Booton-Mander
Marketing Manager
+44 1865 856352

Media Contact:

Joleen Rau
Sr. Director, Marketing Communications
608 218 7623

Media Contacts:

Annabel Entress
+44 207 886 8150
a.entress@northbankcommunications.com
Sarah Jeffery
+44 207 886 8150
s.jeffery@northbankcommunications.com

**OXFORD GENE TECHNOLOGY AND NIMBLEGEN SYSTEMS, INC.
ENTER INTO LICENSING AND SUPPLY AGREEMENTS**

OXFORD, UK, and MADISON, Wis., Jan 8, 2007 – Oxford Gene Technology (OGT) and NimbleGen Systems, Inc. are pleased to announce that NimbleGen has obtained a license to OGT's "Southern array patents," the fundamental patents covering the manufacture and commercialization of oligonucleotide arrays. At the same time the Companies entered into a Supply Agreement under which OGT will be able to obtain DNA microarrays from NimbleGen for use in OGT's service business, and NimbleGen will be able to make and sell OGT-designed arrays. Terms of the agreements were not disclosed.

"Successful discussions with NimbleGen have concluded with the granting of this license thus enabling NimbleGen to deliver their microarray products and services worldwide and adding to OGT's growing portfolio of North American licensees," stated Sue Sutton, Vice President Licensing North America at OGT. "We are also looking forward to being able to offer NimbleGen's high-density microarrays within our microarray service business."

Dr. Stan Rose, President and CEO of NimbleGen, said, "NimbleGen has long been an admirer of the work of Professor Ed Southern, and we're delighted to have expanded our relationship with these new agreements. They provide NimbleGen with access to important intellectual property rights relevant to our core business, as well as an exciting new commercial relationship that should benefit both companies."

About Oxford Gene Technology

- Founded in 1995 by the pioneer of Southern Blotting, Professor Sir Edwin Southern, OGT operates out of Begbroke Business Park near Oxford, with excellent access to a growing network of life science companies.
- OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and recently announced the launch of its first microarray product, an *Escherichia coli* K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT's Prokaryotic Chip² family.

The key focus areas of OGT include:

1. **Array-based application products and services** for life science research and molecular diagnostics. OGT's flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation
2. **Development of innovative platform products** for clinical research and diagnostics
3. **Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
4. **Scientific collaborations** to generate diagnostic biomarker intellectual property

For further information on OGT visit <http://www.ogt.co.uk/>

About NimbleGen Systems, Inc.

NimbleGen Systems, the leading supplier of flexible high-density microarray products and services, is enabling a new era of *High-Definition Genomics*. NimbleGen uniquely produces high-density arrays of isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH, ChIP, microbial Comparative Genome Sequencing, and expression tiling. NimbleGen's High-Definition Genomics enables scientists to obtain and integrate complex genomic data sets not previously accessible, providing a much clearer understanding of genome structure and function, and how this relates to biology and medicine. This improved performance is made possible by NimbleGen's Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize high-density DNA microarrays. For more information about NimbleGen, please visit the company's website at www.nimblegen.com.